Inhibitor Therapeutics, Inc.
INTI· OTC
INTIInhibitor Therapeutics, Inc.
Filed Mar 31, 2023 · 10-K · 90 days after period end · 0001493152-23-010383
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 |
| Net Income | $12.36M | -$33.56K | -$55.85K | -$635.83K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end
